Amincorp Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Amincorp Pharmaceutical Import Records from India — 2 Products, $155.9K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Amincorp — Pharmaceutical Importer Profile (2026) | 2 Products, $155.9K Trade | TransData Nexus

Amincorp

Pharmaceutical Importer · Philippines · Advanced Oncology Focus · $155.9K Total Trade · DGFT Verified

Amincorp is a pharmaceutical importer based in Philippines with a total trade value of $155.9K across 2 products in 1 therapeutic categories. Based on 7 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Amincorp sources from 1 verified Indian supplier, with Bdr Pharmaceuticals International Private Limited accounting for 100.0% of imports.

Amincorp — Import Portfolio & Supplier Network

Amincorp import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Amincorp?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Bdr Pharmaceuticals International Private Limited	$388.2K	18	100.0%

Amincorp sources from 1 verified Indian supplier across 18 distinct formulations. The sourcing is highly concentrated — Bdr Pharmaceuticals International Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Enzalutamide 40 MG capsule bdenza 40 tax document no mh1160000337 dt	$48.7K	1
Enzalutamide 40 MG capsule (tax inv# mh2411600571 dt:25.02.2025) (other)	$47.3K	1
Doripenem (as monohydrate) 500 MG powder for intravenous infusion (drofepen)(other)(tax inv#mh2411600552	$34.5K	1
Lapatinib as ditosylate monohydrate 250MG film coated TAB lapaheal tax inv no mh2511600125 dt 31 05	$32.5K	1
Lapatinib (as ditosylate monohydrate) 250MG film coated TAB (lapaheal)(tax inv# mh2411600497 dt:17.01.2025	$32.4K	1
Lapatinib as distosylate monohydrate	$32.0K	1
Lenvatinib 10MG capsule (bdfoie 10) (other)(tax inv.no: mh2511600015dt:15.04.2025)	$24.5K	1
Boramir INJ (tax inv.no: mh2411600020 dtd.17.04.2024)(lut (arn)no: ad270324101144o dt: 15/03/2024)	$18.6K	1
Bortezomib 3.5MG lyophilized powder for solution for INJ (iv/sc) (boramir) (tax inv.no: mh2511600026	$18.4K	1
Meropenum as trihydrate 1g powderfor injection i v arunem taxinv no mh2511600089 dt 22 05	$17.0K	1
Bd mero 1 GM meropenem powder forinj 1 GM tax inv no mh2511600087 dt 22 05	$17.0K	1
Capecitabine 500MG filmcoated tablet (bdocin 500) (tax inv# mh2411600611 dt:17.03.2025) (other)	$16.1K	1
Lapatinib 250MG tablets (herblock)(other)(tax inv.no: mh2511600020 dt:18.04.2025)	$13.9K	1
Lenvatinib 4MG capsule (bdfoie 4) (other)(tax inv.no: mh2511600014 dt:15.04.2025)	$11.8K	1
Meropenem as trihydrate 500MG powder for injection i v arunem500 tax inv no mh2511600059 dt 09 05	$11.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Lapatinib	Advanced Oncology	$119.5K	5	2.2%	2
2	Lenvatinib	Advanced Oncology	$36.3K	2	1.7%	8

Amincorp imports 2 pharmaceutical products across 1 categories into Philippines totaling $155.9K.

Amincorp — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Amincorp is a pharmaceutical importer and buyer based in the Philippines, specializing in the acquisition of finished pharmaceutical formulations. The company operates as a key player in the Philippine pharmaceutical distribution network, focusing on sourcing and importing medications to meet the local market's therapeutic needs. While specific details about Amincorp's parent company and exact headquarters location are not publicly disclosed, its role in the industry is significant, particularly in the oncology therapeutic category.

2Distribution Network

Amincorp's distribution network encompasses various regions within the Philippines, ensuring that imported pharmaceutical products reach healthcare providers and institutions nationwide. The company collaborates with logistics partners to facilitate the efficient movement of goods from ports of entry to end-users. While specific warehouse locations and logistics capabilities are not publicly detailed, Amincorp's operations are designed to support the timely delivery of medications across the archipelago.

3Industry Role

In the Philippine pharmaceutical supply chain, Amincorp functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from international suppliers, the company plays a crucial role in enhancing the availability of essential medications, particularly in specialized therapeutic areas such as oncology. Amincorp's activities contribute to the diversification of the pharmaceutical market, offering healthcare providers access to a broader range of treatment options.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Amincorp

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Amincorp's sourcing strategy exhibits a high degree of concentration, with all its pharmaceutical imports originating from a single supplier: BDR Pharmaceuticals International Private Limited. This exclusive sourcing arrangement indicates a strategic partnership, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply chain management. However, this dependency also introduces risks, including vulnerability to supply disruptions or changes in supplier terms. The stability of this relationship is evidenced by the consistent volume of shipments over the years, suggesting a mutually beneficial and stable partnership.

2Supply Chain Resilience

Amincorp's supply chain resilience is closely tied to its exclusive relationship with BDR Pharmaceuticals International Private Limited. The lack of backup suppliers may pose challenges in the event of supply chain disruptions. However, the consistent and reliable nature of the partnership with BDR Pharmaceuticals indicates a well-established and dependable supply chain. The focus on a single supplier may also streamline operations and quality control processes, ensuring that imported formulations meet the required standards.

3Strategic Implications

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

In the Philippines, the Food and Drug Administration (FDA) is the primary regulatory body overseeing the importation, manufacture, distribution, and sale of pharmaceutical products. The FDA operates under the Department of Health and is responsible for ensuring that all drugs and medicines meet safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Generics Act of 1988 (Republic Act No. 6675), which promotes the use of generic drugs to make medicines more affordable and accessible. Additionally, the Universally Accessible Cheaper Quality Medicines Act of 2008 (Republic Act No. 9502) further strengthens the regulatory framework by providing mechanisms for the importation of cheaper and quality medicines.

2Import Licensing & GMP

To import pharmaceutical products into the Philippines, companies must obtain a License to Operate (LTO) from the FDA, specifying the "Drug Importer/Wholesaler" category. Each product intended for importation must be registered with the FDA, requiring submission of a Certificate of Pharmaceutical Product (CPP) from the exporting country's regulatory authority, along with evidence of Good Manufacturing Practice (GMP) compliance. Recognized GMP certifications include those from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Additionally, importers must secure accreditation from the Bureau of Customs (BOC) and, if applicable, a permit from the Philippine Drug Enforcement Agency (PDEA) for controlled substances.

Amincorp — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Amincorp's focus on importing finished pharmaceutical formulations, particularly in the oncology therapeutic category, aligns with the growing demand for cancer treatments in the Philippines. The decision to import specific products such as Lapatinib and Lenvatinib suggests a strategic approach to address unmet medical needs and provide patients with access to essential therapies. Market demand for these medications is driven by the increasing prevalence of cancer and the need for effective treatment options.

2Sourcing Profile

Amincorp's sourcing strategy centers on importing generic drugs from India, leveraging the country's robust pharmaceutical manufacturing sector known for producing high-quality medications at competitive prices. The company's preference for finished pharmaceutical formulations indicates a focus on ready-to-market products, streamlining the importation process and reducing time to market. India's compliance with international GMP standards and its extensive product portfolio make it a suitable partner for Amincorp's procurement needs.

3Market Positioning

Amincorp serves the Philippine pharmaceutical market by importing and distributing specialized oncology medications. The company's product mix positions it to cater to healthcare providers, including hospitals and specialized clinics, that require access to advanced cancer treatments. By focusing on high-demand therapeutic areas and ensuring a reliable supply of essential medications, Amincorp plays a vital role in enhancing the quality of healthcare services available to patients.

Seller's Guide — How to Become a Supplier to Amincorp

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Amincorp, especially if they can offer competitive pricing and high-quality generic formulations that meet the therapeutic needs of the Philippine market. Amincorp's current sourcing strategy, which relies on a single supplier, presents an opportunity for diversification, potentially enhancing supply chain resilience and mitigating risks associated with single-source dependency. Indian exporters can explore this opportunity by ensuring compliance with Philippine regulatory requirements and demonstrating the value of their products in addressing local healthcare needs.

2Requirements & Qualifications

Indian exporters seeking to supply Amincorp and the Philippine market must ensure that their products are registered with the Philippine FDA and comply with GMP standards recognized by the FDA. They must provide a Certificate of Pharmaceutical Product (CPP) from the exporting country's regulatory authority and adhere to labeling requirements, including the use of the English language and specific product information. Additionally, exporters should be prepared to navigate the import licensing process, which involves obtaining the necessary permits and approvals from Philippine authorities.

How to Approach

Frequently Asked Questions — Amincorp

What products does Amincorp import from India?

Amincorp imports 2 pharmaceutical products across 1 categories. Top imports: Lapatinib ($119.5K), Lenvatinib ($36.3K).

Who supplies pharmaceuticals to Amincorp from India?

Amincorp sources from 1 verified Indian suppliers. The primary supplier is Bdr Pharmaceuticals International Private Limited (100.0% of imports, $388.2K).

What is Amincorp's total pharmaceutical import value?

Amincorp's total pharmaceutical import value from India is $155.9K, based on 7 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Amincorp focus on?

Amincorp imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Amincorp Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.